GlobeNewsWire
25 Nov 2025, 12:01 UTC · 41w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Invivyd is conducting the LIBERTY clinical trial to evaluate the safety and tolerability of VYD2311 compared to mRNA COVID-19 vaccines. — Clinical trial outcomes for pipeline products are primary drivers of valuation for biopharmaceutical companies.
+0.40Invivyd management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025. — Investor conferences can lead to short-term volatility or positive sentiment if new guidance is provided, but the event itself is routine.
+0.10Invivyd granted stock options to 17 newly hired non-executive employees on June 1, 2026. — Standard administrative hiring and compensation activity with negligible impact on market price.
+0.00Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
The company is participating in a healthcare conference and mentioning its FDA emergency use authorization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
